KUALA LUMPUR: A detailed explanation must be given as to why the government decided to procure the antiviral medicine Molnupiravir for Covid-19 treatment, says Datuk Seri Dr Ahmad Zahid Hamidi. On Thursday (Oct 7), Malaysia signed an agreement with Merck Sharp & Dohme (MSD) to procure antiviral medicine Molnupiravir for Covid-19 treatment. Health Minister Khairy Jamaluddin said the government signed a letter of undertaking on Oct 7 to procure 150,000 courses of Molnupiravir to treat Covid-19 patients. "Baricitinib, together with Remdesivir were said to have shown proven effectiveness in treating Covid-19 patients based on international research. "There is a need for clarification about the matter in order to convince the people about the government's decision to use Molnupiravir," said Ahmad Zahid.
